Saturday, January 31, 2015 11:04:09 AM
You did not say explicitly over vaccines. But priority has to be over something else and since vaccines were the only other thing under discussion and the only remotely comparable alternative, IMHO it was reasonable (unavoidable really) to interpret your statement that drugs should get priority over vaccines.
ANd I responded by presenting highly detailed arguments why vaccines should get priority over drugs. Just as you never said that vaccines should not be developed and used, in equal fashion I never remotely said that drugs should not be developed and used.
And you have presented no evidence nor counterarguments whatsoever to oppose my contention that vaccines should get PRIORITY (NOT saying REPLACE)
Clearly the WHO and CIDRAP both share my view (about vaccines getting priority over drugs.
CIDRAP recently released a report on "Fast Tracking the Development of Ebola VACCINES" which barely mentioned drugs at all, and only in passing. And no comparable document on fast tracking the development of drugs.
This is because, while an effective drug can save lives, it cannot significantly slow or prevent the spread of an outbreak. An effective vaccine can bring an outbreak to a very rapid stop (even without vaccinating the entire population due to "herd immunity" (again, one cannot understand either drugs nor vaccines' effects on pandemics and disease without understanding the concept of herd immunity)
-----------
the above was RE"You also fail to respond to my point that it would be difficult or impossible to inoculate large populations in third-world countries who believe that illnesses like HIV and Ebola were caused by Westerners who (in their opinions falsely) claimed to be providing medical care."
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM